Alucio™ Continues Its Customer Expansion with Phathom Pharmaceuticals


News Image

“We are very excited and appreciative that Phathom selected Beacon to power their medical affairs activities as they develop innovative treatments for GI-related disorders”, said Dave Gulezian, Co-Founder & CEO of Alucio, “We look forward to ensuring their success with the platform.”

Alucio™, a fast-growing provider of cloud-based software for the life sciences industry, today announced that Phathom Pharmaceuticals (Phathom) has selected Alucio’s Beacon platform for use by their Medical Affairs and Field Medical teams. Beacon is a modern content activation and healthcare professionals (HCP) engagement platform built specifically for Medical Science Liaisons (MSLs), Medical Affairs professionals, and Market Access teams.

Through this agreement, Alucio will support Phathom in realizing their scientific exchange objectives as they work to improve the treatment landscape for patients suffering from acid-related gastrointestinal (GI) disorders. Phathom will leverage Beacon’s powerful content library management and on-demand publishing functionality to organize and distribute documents to the MSL team.

Beacon will also compliantly enable MSLs to assemble custom presentations to meet the specific information needs of their Key Opinion Leaders (KOLs). Additionally, Beacon’s hybrid engagement functionality will provide unique, industry-specific features to enrich their virtual meetings across leading video conferencing platforms like Zoom, as well as to power in-person meetings where data service is unavailable.

Through Beacon, Phathom will be able to access relevant content and engagement data through user-friendly reports and dashboards to support its strategic decision making.

Phathom adds to Alucio’s fast-growing roster of life science companies that have become Beacon customers. The platform can support both large and small pharma, biotech, and medical device companies seeking to manage and distribute scientific content more efficiently and to deepen their relationships with both medical KOLs and payers.

“We are very excited and appreciative that Phathom selected Beacon to power their medical affairs activities as they develop innovative treatments for GI-related disorders”, said Dave Gulezian, Co-Founder & CEO of Alucio, “We look forward to ensuring their success with the platform and to deepening our partnership as they move towards commercialization.”

About Alucio:

Alucio is dedicated to the development of innovative software applications specifically for the life sciences industry. Alucio’s flagship product, Beacon, is a modern, cloud-based scientific exchange platform that enhances scientific dialogue and engagement between life science companies and healthcare professionals. For more information, please visit the company’s website at http://www.alucio.io or contact: Lisa Amin at lamin@alucio.io (925) 788-3533.

Share article on social media or email:

Leave a Reply